Author: Sainsbury, Christopher; Wang, Jingya; Gokhale, Krishna; Acostaâ€Mena, Dionisio; Dhalla, Samir; Byne, Nathan; Chandan, Joht Singh; Anand, Astha; Cooper, Jennifer; Okoth, Kelvin; Subramanian, Anuradhaa; Bangash, Mansoor N; Taverner, Thomas; Hanif, Wasim; Ghosh, Sandip; Narendran, Parth; Cheng, Kar Keung; Marshall, Tom; Gkoutos, Georgios; Toulis, Konstantinos; Thomas, Neil; Tahrani, Abd; Adderley, Nicola J; Haroon, Shamil; Nirantharakumar, Krishnarajah
Title: Sodiumâ€glucoseâ€coâ€transporterâ€2 inhibitors and susceptibility to COVIDâ€19: a populationâ€based retrospective cohort study Cord-id: y02arv25 Document date: 2020_9_29
ID: y02arv25
Snippet: Sodium/glucose coâ€transporterâ€2 inhibitors (SGLT2i) are widely prescribed in people with type 2 diabetes. We aimed to investigate whether SGLT2i prescription is associated with COVIDâ€19, when compared with an active comparator. We performed a propensity scoreâ€matched cohort study with active comparators and a negative control outcome in a large UKâ€based primary care dataset. Participants prescribed SGLT2i (n = 9948) and a comparator group prescribed dipeptylâ€peptidase 4 inhibitors (D
Document: Sodium/glucose coâ€transporterâ€2 inhibitors (SGLT2i) are widely prescribed in people with type 2 diabetes. We aimed to investigate whether SGLT2i prescription is associated with COVIDâ€19, when compared with an active comparator. We performed a propensity scoreâ€matched cohort study with active comparators and a negative control outcome in a large UKâ€based primary care dataset. Participants prescribed SGLT2i (n = 9948) and a comparator group prescribed dipeptylâ€peptidase 4 inhibitors (DPP4i; n = 14 917) were followed up from 30th January to 27th July 2020. The primary outcome was confirmed or clinically suspected COVIDâ€19. The incidence rate of COVIDâ€19 was 19.7/1000 personâ€years among users of SGLT2i and 24.7/1000 personâ€years among propensity score matched users of DPP4i. The adjusted hazard ratio was 0.92 (95% CI 0.66 to 1.29) and there was no evidence of residual confounding in the negative control analysis. We did not observe an increased risk of COVIDâ€19 in primary care amongst those prescribed SGLT2i compared to DPP4i, suggesting that clinicians may safely use these agents in the everyday care of people with type 2 diabetes during the COVIDâ€19 pandemic. This article is protected by copyright. All rights reserved.
Search related documents:
Co phrase search for related documents- active comparator and acute respiratory: 1, 2, 3, 4, 5, 6, 7
- active comparator and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
- active comparator and adjusted hr: 1
- active patient and acute illness: 1, 2
- active patient and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- active patient and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute illness and long term management: 1, 2, 3, 4, 5, 6
- acute respiratory and adjusted crude: 1, 2, 3, 4, 5, 6
- acute respiratory and adjusted crude hazard ratio: 1
- acute respiratory and adjusted hr: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and long term management: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and adjusted crude: 1, 2, 3, 4, 5
- acute respiratory syndrome and adjusted crude hazard ratio: 1
- acute respiratory syndrome and adjusted hr: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and long term management: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date